VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders

VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders

Publication date: Jun 26, 2020

Collaboration intended to support Phase 3 development and commercialization of PH94B in key Asian markets San Francisco, United States – June 25, 2020 /MarketersMedia/ – VistaGen Therapeutics, a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) diseases and disorders with high unmet need, and EverInsight Therapeutics Inc. , a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced they have entered into a strategic licensing and collaboration agreement for the clinical development and commercialization of PH94B, VistaGen’s novel, rapid-onset neurosteroid drug candidate for multiple anxiety-related disorders, in Greater China, South Korea and Southeast Asia.

The goal of the collaboration is to advance and support Phase 3 development and commercialization of PH94B as a potentially groundbreaking anti-anxiety medicine for patients in Greater China and other important Asian markets.

Under the terms of the agreement, EverInsight will be responsible for clinical development, regulatory submissions and commercialization of PH94B neuroactive nasal spray for acute treatment of SAD, and potentially other anxiety-related indications, in markets in Greater China (Mainland China, Hong Kong, Macau and Taiwan), South Korea and Southeast Asia (Indonesia, Malaysia, Philippines, Thailand and Vietnam) (the Territory).

EverInsight is an ideal partner to support Phase 3 clinical development and commercial launch of PH94B in Greater China and other Asian markets, as we continue to focus on those activities in the U. S.,” stated Shawn Singh, Chief Executive Officer of VistaGen.

About VistaGen VistaGen Therapeutics is a multi-asset, clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and certain CNS diseases and disorders where current treatments are inadequate, resulting in high unmet need.

For more information, please visit www. vistagen. com and connect with VistaGen on EverInsight Therapeutics EverInsight Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs in CNS and ophthalmology for patients in Greater China and other Asian markets.

Concepts Keywords
Anxiety Regulus Therapeutics
Anxiety Disorders Biopharmaceutical
Asia Social anxiety disorder
Asian Emotions
Asset Anxiety disorders
Beijing Psychiatric diagnosis
Biopharmaceutical Psychiatry
Biotech Articles
CBC Life sciences
Central Nervous System Illness
Chief Executive Officer SAD
China Medicines anxiety depression
Depression Social anxiety disorder
Fast Track Designation Numerous anxiety disorders
FDA Healthcare sector champions
Greater China Pharmaceutical biotech medtech
Healthcare Transformative pharmaceutical products
Hong Kong Active healthcare
Inadequate Stage biopharmaceutical
Indonesia
Macau
Mainland China
Malaysia
Nasal Spray
Neurosteroid
Ophthalmology
Pandemic
Paradigm
Pharmaceutical
Pharmaceutical Companies
Philippines
Portfolio Management
Royalties
Shanghai
Singapore
Social Anxiety Disorder
Social Justice
South Korea
Southeast Asia
Suicide
Taiwan
Thailand
Vietnam

Semantics

Type Source Name
drug DRUGBANK PH94B
disease MESH anxiety
drug DRUGBANK Etoperidone
disease MESH development
pathway REACTOME Release
disease MESH Anxiety Disorders
drug DRUGBANK Coenzyme M
disease MESH CNS diseases
disease MESH suicide
disease MESH social anxiety disorder
drug DRUGBANK Nonoxynol-9
disease MESH depression

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *